CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性白血病中的免疫治疗
英文原题：Immunotherapies in acute leukemia.
查看英文原题
Immunotherapies in acute leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年间，免疫治疗已成为急性白血病领域最有前景的治疗进展之一。抗体药物偶联物目前已与标准化疗方案联合用于急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）。靶向CD19的免疫细胞衔接器及嵌合抗原受体（CAR）T细胞已获批用于复发/难治性B细胞急性淋巴细胞白血病，也为其在急性髓系白血病中的应用带来了有前景的发展方向。新一代免疫检查点抑制剂包括靶向TIM-3的药物，以及阻断CD47与巨噬细胞SIRP结合的药物；这些药物正与去甲基化药物联合开展研究，以期在可接受的安全性下改善身体状况较差的AML患者生存。本综述概述急性白血病领域开发的抗体衍生治疗策略，并重点介绍近期获批药物。
展开英文摘要原文
In the past decade, immunotherapy has emerged as one of the most promising field of therapeutic progress in acute leukemia. Antibody-drug conjugates are now combined to standard chemotherapy backbones in both acute myeloid (AML) and lymphoblastic leukemia (ALL). CD19 targeting immune cell engagers and chimeric antigen receptor (CAR) T-cells have been approved in relapsed/refractory B-cell acute lymphoblastic leukemia and pave the way to promising developments in acute myeloid leukemia.
Next generation immune checkpoint inhibitors targeting TIM-3 or CD47 binding by SIRP on macrophages are tested in combination to hypomethylating agents to improve survival of unfit AML patients with acceptable safety profiles. This review summarizes the antibody-derived strategies developed in the field of acute leukemias with a specific focus on recently approved drugs.
论文信息
- 作者
- Boissel N、Rabian F
- 单位
- Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; URP-3518, Institut de Recherche Saint-Louis, Université de Paris, 75010 Paris, France. Electronic address: nicolas.boissel@aphp.fr.France
- 文献类型
- 综述
- 期刊
- Therapie2022 Mar-Apr
- 原文标识
- PubMed 34924207 · DOI 10.1016/j.therap.2021.12.003